<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>316</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15105530</PubmedId>
            <Abstract>Our earlier identification of the non-structural protein 3 (NS3) of Japanese encephalitis virus (JEV) as a dominant CD4+ as well as CD8+ T cell-eliciting antigen in a healthy JEV-endemic cohort with a wide HLA distribution implied the presence of several epitopes dispersed over the length of the protein. Use of various truncated versions of NS3 in lymphocyte stimulation and interferon (IFN)-gamma secretion assays revealed that amino acids (aa) 193-324 of NS3 were comparable with, if not superior to, the full-length protein in evoking Th1 responses. The potential of this 14.4 kDa stretch to stimulate IFN-gamma production from both subtypes of T cells in a manner qualitatively and quantitatively similar to the 68 kDa parent protein suggested the presence within it of both class I and II epitopes and demonstrated that the entire immunogenicity of NS3 was focused on aa 193-324. Interestingly, this segment contained five of the eight helicase motifs of NS3. Analysis of variability of the NS3 protein sequence across 16 JEV isolates revealed complete identity of aa 219-318, which is contained within the above segment, suggesting that NS3-specific epitopes tend to cluster in relatively conserved regions that harbour functionally critical domains of the protein.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>1131-1143</ArticlePages>
            <ArticleTitle>Conserved amino acids 193-324 of non-structural protein 3 are a dominant source of peptide determinants for CD4+ and CD8+ T cells in a healthy Japanese encephalitis virus-endemic cohort.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Kumar</LastName>
                    <ForeName>Priti</ForeName>
                </Author>
                <Author>
                    <LastName>Sulochana</LastName>
                    <ForeName>Paramadevanapalli</ForeName>
                </Author>
                <Author>
                    <LastName>Nirmala</LastName>
                    <ForeName>Gejjehalli</ForeName>
                </Author>
                <Author>
                    <LastName>Haridattatreya</LastName>
                    <ForeName>Maganti</ForeName>
                </Author>
                <Author>
                    <LastName>Satchidanandam</LastName>
                    <ForeName>Vijaya</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka 560012, India; Department of Pediatrics, Vijayanagar Institute of Medical Sciences, Bellary, Karnataka 583104, India.</Affiliations>
            <ArticleChemicalList>Antigens, Viral;Epitopes;NS3 protein, flavivirus;Viral Nonstructural Proteins;Interferon-gamma;Serine Endopeptidases;RNA Helicases</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adolescent; Amino Acid Sequence; Antigens, Viral(genetics; immunology); CD4-Positive T-Lymphocytes(immunology); CD8-Positive T-Lymphocytes(immunology); Cells, Cultured; Child; Child, Preschool; Encephalitis Virus, Japanese(immunology); Encephalitis, Japanese(epidemiology; immunology); Endemic Diseases; Epitopes(immunology); Female; Humans; Immunity, Cellular; India(epidemiology); Interferon-gamma(biosynthesis); Male; Molecular Sequence Data; RNA Helicases; Serine Endopeptidases; Viral Nonstructural Proteins(genetics; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>85</Volume>
                <Issue>Pt 5</Issue>
                <Title>The Journal of general virology</Title>
                <Issn>0022-1317</Issn>
                <MedlineTa>J Gen Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>JEV NS3 (193-324)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DLHPGSGKTRKILPQIIKDAIQQRLRTAVLAPTRVVAAEMAEALRGLPVRYQTSAVQREHQGNEIVDVMCHATLTHRLMSPNRVPNYNLFVMDEAHFTDPASIAARGYIATKVELGEAAAIFMTATPPGTTDPFPDSNAPIH</LinearSequence>
                        <StartingPosition>1697</StartingPosition>
                        <EndingPosition>1838</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAC29474.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10001335</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>116289</EpitopeId>
                <ReferenceStartingPosition>193</ReferenceStartingPosition>
                <ReferenceEndingPosition>324</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Author provided Identifier</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 3B, 4A, C</LocationOfData>
                        <TCellId>1661035</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <GeoLocId>http://purl.obolibrary.org/obo/GAZ_00002839</GeoLocId>
                                <Age>5-16 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:10844</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11072</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>JEV</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Twenty-six healthy non-vaccinated JEV-seropositive children (15 males, 11 females, 5–16 years old, mean age 9.6 ± 0.6 years) with no history of clinical encephalitis, but with &gt;1 log10 serum plaque reduction neutralization test (PRNT) antibody titers to JEV, as well as serum antibodies to non-structural proteins by radioimmunoprecipitation, constituted the test group having experienced previous subclinical JEV infections. Serum PRNT-ELISAs to dengue and West Nile viruses were confirmed to be negative.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>304</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NS3 (193-324)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DLHPGSGKTRKILPQIIKDAIQQRLRTAVLAPTRVVAAEMAEALRGLPVRYQTSAVQREHQGNEIVDVMCHATLTHRLMSPNRVPNYNLFVMDEAHFTDPASIAARGYIATKVELGEAAAIFMTATPPGTTDPFPDSNAPIH</LinearSequence>
                                        <StartingPosition>1697</StartingPosition>
                                        <EndingPosition>1838</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAC29474.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10001335</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>26</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>23</NumberOfSubjectsResponded>
                            <ResponseFrequency>88.5</ResponseFrequency>
                            <AssayComments>The epitope, aa193-324, was found to be the dominant NS3-reactive fragment in JEV-exposed children. No difference was observed when responses to aa193-324 were compared to full-length NS3.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4B, C</LocationOfData>
                        <TCellId>1661039</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <GeoLocId>http://purl.obolibrary.org/obo/GAZ_00002839</GeoLocId>
                                <Age>5-16 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:10844</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11072</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>JEV</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Twenty-six healthy non-vaccinated JEV-seropositive children (15 males, 11 females, 5–16 years old, mean age 9.6 ± 0.6 years) with no history of clinical encephalitis, but with &gt;1 log10 serum plaque reduction neutralization test (PRNT) antibody titers to JEV, as well as serum antibodies to non-structural proteins by radioimmunoprecipitation, constituted the test group having experienced previous subclinical JEV infections. Serum PRNT-ELISAs to dengue and West Nile viruses were confirmed to be negative.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>NS3 (193-324)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DLHPGSGKTRKILPQIIKDAIQQRLRTAVLAPTRVVAAEMAEALRGLPVRYQTSAVQREHQGNEIVDVMCHATLTHRLMSPNRVPNYNLFVMDEAHFTDPASIAARGYIATKVELGEAAAIFMTATPPGTTDPFPDSNAPIH</LinearSequence>
                                        <StartingPosition>1697</StartingPosition>
                                        <EndingPosition>1838</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAC29474.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10001335</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>73</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>23</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>18</NumberOfSubjectsResponded>
                            <ResponseFrequency>78.3</ResponseFrequency>
                            <AssayComments>The epitope, aa193-324, was found to be the dominant NS3-reactive fragment in JEV-exposed children. No difference was observed when responses to aa193-324 were compared to full-length NS3.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5 and Table 1</LocationOfData>
                        <TCellId>1661041</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <GeoLocId>http://purl.obolibrary.org/obo/GAZ_00002839</GeoLocId>
                                <Age>5-16 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:10844</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11072</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>JEV</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Twenty-six healthy non-vaccinated JEV-seropositive children (15 males, 11 females, 5–16 years old, mean age 9.6 ± 0.6 years) with no history of clinical encephalitis, but with &gt;1 log10 serum plaque reduction neutralization test (PRNT) antibody titers to JEV, as well as serum antibodies to non-structural proteins by radioimmunoprecipitation, constituted the test group having experienced previous subclinical JEV infections. Serum PRNT-ELISAs to dengue and West Nile viruses were confirmed to be negative.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>303</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -T cell subset identification</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NS3 (193-324)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DLHPGSGKTRKILPQIIKDAIQQRLRTAVLAPTRVVAAEMAEALRGLPVRYQTSAVQREHQGNEIVDVMCHATLTHRLMSPNRVPNYNLFVMDEAHFTDPASIAARGYIATKVELGEAAAIFMTATPPGTTDPFPDSNAPIH</LinearSequence>
                                        <StartingPosition>1697</StartingPosition>
                                        <EndingPosition>1838</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAC29474.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10001335</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>18</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>17</NumberOfSubjectsResponded>
                            <ResponseFrequency>94.4</ResponseFrequency>
                            <AssayComments>The epitope, aa193-324, was found to be the dominant NS3-reactive fragment in JEV-exposed children. This epitope stimulated IFNg production in both CD4 and CD8 T cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5 and Table 1</LocationOfData>
                        <TCellId>1661040</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <GeoLocId>http://purl.obolibrary.org/obo/GAZ_00002839</GeoLocId>
                                <Age>5-16 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:10844</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Parent</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11072</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>JEV</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Twenty-six healthy non-vaccinated JEV-seropositive children (15 males, 11 females, 5–16 years old, mean age 9.6 ± 0.6 years) with no history of clinical encephalitis, but with &gt;1 log10 serum plaque reduction neutralization test (PRNT) antibody titers to JEV, as well as serum antibodies to non-structural proteins by radioimmunoprecipitation, constituted the test group having experienced previous subclinical JEV infections. Serum PRNT-ELISAs to dengue and West Nile viruses were confirmed to be negative.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>304</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -T cell subset identification</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NS3 (193-324)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DLHPGSGKTRKILPQIIKDAIQQRLRTAVLAPTRVVAAEMAEALRGLPVRYQTSAVQREHQGNEIVDVMCHATLTHRLMSPNRVPNYNLFVMDEAHFTDPASIAARGYIATKVELGEAAAIFMTATPPGTTDPFPDSNAPIH</LinearSequence>
                                        <StartingPosition>1697</StartingPosition>
                                        <EndingPosition>1838</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAC29474.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10001335</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>18</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>17</NumberOfSubjectsResponded>
                            <ResponseFrequency>94.4</ResponseFrequency>
                            <AssayComments>The epitope, aa193-324, was found to be the dominant NS3-reactive fragment in JEV-exposed children. This epitope stimulated IFNg production in both CD4 and CD8 T cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

